Attitudes toward Vaccination against COVID-19 in Poland. A Longitudinal Study Performed before and Two Months after the Commencement of the Population Vaccination Programme in Poland
Abstract
1. Introduction
2. Materials and Methods
2.1. Methods
2.2. Statistical Analysis
3. Results
3.1. Participants
3.2. Approach to Vaccination
3.3. Influencing Factors
3.4. Analysis of Concerns Related to Vaccination against COVID-19
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19. 3 March 2020. Available online: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---3-march-2020 (accessed on 26 April 2021).
- Mancilla-Galindo, J.; García-Méndez, J.Ó.; Márquez-Sánchez, J.; Reyes-Casarrubias, R.E.; Aguirre-Aguilar, E.; Rocha-González, H.I.; Kammar-García, A. All-cause mortality among patients treated with repurposed antivirals and antibiotics for COVID-19 in Mexico City: A real-world observational study. EXCLI J. 2021, 20, 199–222. [Google Scholar] [PubMed]
- Alzoughool, F.; Alanagreh, L. Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19. Int. J. Risk Saf. Med. 2020, 31, 47–51. [Google Scholar] [CrossRef] [PubMed]
- Pfizer Oraz BioNTech Pracują Nad Rozwojem Potencjalnej Szczepionki na COVID-19. Available online: https://www.pfizer.com.pl/o-firmie/press-room/pfizer-oraz-biontech-pracuj%C4%85-nad-rozwojem-potencjalnej-szczepionki-na-covid-19 (accessed on 26 April 2021).
- EMA Recommends First COVID-19 Vaccine for Authorisation in the EU. Available online: https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu (accessed on 26 April 2021).
- EMA Recommends COVID-19 Vaccine AstraZeneca for Authorisation in the EU. Available online: https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu (accessed on 26 April 2021).
- EMA Recommends COVID-19 Vaccine Moderna for Authorisation in the EU. Available online: https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu (accessed on 26 April 2021).
- EMA Recommends COVID-19 Vaccine Janssen for Authorisation in the EU. Available online: https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-janssen-authorisation-eu (accessed on 26 April 2021).
- Rzymski, P.; Borkowski, L.; Drąg, M.; Flisiak, R.; Jemielity, J.; Krajewski, J.; Mastalerz-Migas, A.; Matyja, A.; Pyrć, K.; Simon, K.; et al. The strategies to support the COVID-19 vaccination with evidence-based communication and tackling misinformation. Vaccines 2021, 9, 109. [Google Scholar] [CrossRef] [PubMed]
- Anderson, R.M.; Vegvari, C.; Truscott, J.; Collyer, B.S. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet 2020, 396, 1614–1616. [Google Scholar] [CrossRef]
- Neumann-Böhme, S.; Varghese, N.E.; Sabat, I.; Barros, P.P.; Brouwer, W.; van Exel, J.; Schreyögg, J.; Stargardt, T. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. Eur. J. Health Econ. 2020, 21, 977–982. [Google Scholar] [CrossRef] [PubMed]
- Sallam, M. COVID-19 vaccine hesitancy worldwide: A concise systematic review of vaccine acceptance rates. Vaccines 2021, 9, 160. [Google Scholar] [CrossRef]
- W Polsce Ruszyły Szczepienia Przeciw COVID-19—“To Historyczny Moment”—Szczepienie Przeciwko COVID-19—Portal Gov.pl. Available online: https://www.gov.pl/web/szczepimysie/w-polsce-ruszyly-szczepienia-przeciw-covid-19--to-historycznymoment?utm_source=google&utm_medium=cpc&utm_campaign=WH_SEA_DSA_Koronawirus&utm_term=&utm_content=492347959679 (accessed on 26 April 2021).
- Ruszają Szczepienia Osób 70+. Ponad 60% Polaków Jest Na “Tak”—Szczepienie Przeciwko COVID-19—Portal Gov.pl. Available online: https://www.gov.pl/web/szczepimysie/ruszaja-szczepienia-osob-70-ponad-60-polakow-jest-na-tak (accessed on 26 April 2021).
- Rozporządzenie Rady Ministrów z Dnia 21 Grudnia 2020 r. w Sprawie Ustanowienia Określonych Ograniczeń, Nakazów i Zakazów w Związku z Wystąpieniem Stanu Epidemii. Available online: https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20200002316 (accessed on 26 April 2021).
- Rozporządzenie Rady Ministrów z Dnia 14 Stycznia 2021 r. Zmieniające Rozporządzenie w Sprawie Ustanowienia Określonych Ograniczeń, Nakazów i Zakazów w Związku z Wystąpieniem Stanu Epidemii. Available online: https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20210000091 (accessed on 26 April 2021).
- Rozporządzenie Rady Ministrów z Dnia 11 Lutego 2021 r. Zmieniające Rozporządzenie w Sprawie Ustanowienia Określonych Ograniczeń, Nakazów i Zakazów w Związku z Wystąpieniem Stanu Epidemii. Available online: https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20210000267 (accessed on 26 April 2021).
- Rozporządzenie Rady Ministrów z Dnia 11 Marca 2021 r. Zmieniające Rozporządzenie w Sprawie Ustanowienia Określonych Ograniczeń, Nakazów i Zakazów w Związku z Wystąpieniem Stanu Epidemii. Available online: https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20210000446 (accessed on 26 April 2021).
- Coronavirus (COVID-19) Vaccinations. Available online: https://ourworldindata.org/covid-vaccinations (accessed on 26 April 2021).
- Lazarus, J.V.; Ratzan, S.C.; Palayew, A.; Gostin, L.O.; Larson, H.J.; Rabin, K.; Kimball, S.; El-Mohandes, A. A global survey of potential acceptance of a COVID-19 vaccine. Nat. Med. 2021, 27, 225–228. [Google Scholar] [CrossRef]
- García, L.Y.; Cerda, A.A. Contingent assessment of the COVID-19 vaccine. Vaccine 2020, 38, 5424–5429. [Google Scholar] [CrossRef]
- Ceulemans, M.; Foulon, V.; Panchaud, A.; Winterfeld, U.; Pomar, L.; Lambelet, V.; Cleary, B.; O’Shaughnessy, F.; Passier, A.; Richardson, J.L.; et al. Vaccine willingness and impact of the COVID-19 pandemic on women’s perinatal experiences and practices—A multinational, cross-sectional study covering the first wave of the pandemic. Int. J. Environ. Res. Public Health 2021, 18, 3367. [Google Scholar] [CrossRef] [PubMed]
- Szilagyi, P.G.; Thomas, K.; Shah, M.D.; Vizueta, N.; Cui, Y.; Vangala, S.; Kapteyn, A. National trends in the US public’s likelihood of getting a COVID-19 vaccine-April 1 to December 8, 2020. J. Am. Med. Assoc. 2020, 325, 396. [Google Scholar] [CrossRef] [PubMed]
- Lopez Bernal, J.; Andrews, N.; Gower, C.; Stowe, J.; Robertson, C.; Tessier, E.; Simmons, R.; Cottrell, S.; Robertson, R.; O’Doherty, M.; et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. medRxiv 2021. [Google Scholar] [CrossRef]
- Karlsson, L.C.; Soveri, A.; Lewandowsky, S.; Karlsson, L.; Karlsson, H.; Nolvi, S.; Karukivi, M.; Lindfelt, M.; Antfolk, J. Fearing the disease or the vaccine: The case of COVID-19. Pers. Individ. Dif. 2021, 172, 110590. [Google Scholar] [CrossRef] [PubMed]
- Raport Szczepień Przeciwko COVID-19—Szczepienie Przeciwko COVID-19—Portal Gov.pl. Available online: https://www.gov.pl/web/szczepimysie/raport-szczepien-przeciwko-covid-19 (accessed on 26 April 2021).
- Tian, T.; Zhang, J.; Hu, L.; Jiang, Y.; Duan, C.; Li, Z.; Wang, X.; Zhang, H. Risk factors associated with mortality of COVID-19 in 3125 counties of the United States. Infect. Dis. Poverty 2021, 10, 3. [Google Scholar] [CrossRef] [PubMed]
- Dror, A.A.; Eisenbach, N.; Taiber, S.; Morozov, N.G.; Mizrachi, M.; Zigron, A.; Srouji, S.; Sela, E. Vaccine hesitancy: The next challenge in the fight against COVID-19. Eur. J. Epidemiol. 2020, 35, 775–779. [Google Scholar] [CrossRef] [PubMed]
- Gagneux-Brunon, A.; Detoc, M.; Bruel, S.; Tardy, B.; Rozaire, O.; Frappe, P.; Botelho-Nevers, E. Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: A cross-sectional survey. J. Hosp. Infect. 2021, 108, 168–173. [Google Scholar] [CrossRef]
- Grech, V.; Bonnici, J.; Zammit, D. WITHDRAWN: Vaccine hesitancy in Maltese family physicians and their trainees vis-à-vis influenza and novel COVID-19 vaccination. Early Hum. Dev. 2020, 105259. [Google Scholar] [CrossRef] [PubMed]
- AZ Covid-19 Vaccine Is Suspended by EU Countries. Available online: https://www.pharmaceutical-technology.com/news/european-countries-suspend-covid-19-az/ (accessed on 26 April 2021).
- COVID-19 Vaccine AstraZeneca: Benefits Still Outweigh the Risks Despite Possible Link to Rare Blood Clots with Low Blood Platelets. Available online: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots (accessed on 26 April 2021).
- Babicki, M.; Szewczykowska, I.; Mastalerz-Migas, A. Mental health in the era of the second wave of SARS-CoV-2: A cross-sectional study based on an online survey among online respondents in Poland. Int. J. Environ. Res. Public Health 2021, 18, 2522. [Google Scholar] [CrossRef] [PubMed]
- Yaqub, O.; Castle-Clarke, S.; Sevdalis, N.; Chataway, J. Attitudes to vaccination: A critical review. Soc. Sci. Med. 2014, 112, 1–11. [Google Scholar] [CrossRef] [PubMed]
Variable | Stage I (n = 463) | Stage II (n = 1559) | p | |
---|---|---|---|---|
Age | 18–29 | 183 (39.5%) | 774 (49.7%) | <0.001 |
30–39 | 131 (28.3%) | 457 (29.3%) | ||
40–59 | 127 (27.4%) | 277 (17.8%) | ||
≥60 | 22 (4.8%) | 51 (3.3%) | ||
Gender | Male | 114 (24.6%) | 265 (17%) | 0.002 |
Female | 349 (75.4%) | 1294 (83%) | ||
Place of residence | Rural area | 96 (20.7%) | 340 (21.8%) | 0.184 |
City <50,000 residents | 87 (18.8%) | 264 (16.9%) | ||
City of 50,000–250,000 residents | 103 (22.3%) | 291 (18.7%) | ||
City >250,000 residents | 177 (38.2%) | 664 (42.6%) | ||
Level of education | Primary | 1 (0.2%) | 10 (0.6%) | 0.267 |
Lower secondary | 5 (1%) | 8 (0.5%) | ||
Vocational | 18 (3.9%) | 40 (2.6%) | ||
Secondary education | 136 (29.5%) | 462 (29.6%) | ||
University degree | 303 (65.4%) | 1039 (66.7%) | ||
Relationship status | Married | 212 (45.8%) | 688 (44.1%) | 0.845 |
Civil partnership/Informal relationship | 147 (31.8%) | 504 (32.4%) | ||
I am not in a relationship | 104 (22.4%) | 367 (23.5%) | ||
Healthcare professional | Yes | 108 (23.3%) | 313 (20.8%) | 0.131 |
No | 355 (76.7%) | 1246 (79.2%) | ||
COVID-19 diagnosis | In the course of the illness | 5 (1%) | 22 (1.4%) | 0.472 |
Convalescent | 69 (15%) | 265 (17%) | ||
Has not been ill | 389 (84%) | 1271 (81.6%) | ||
Chronic conditions | Yes | - | 529 (34%) | - |
No | - | 1030 (66%) | ||
Person vaccinated against COVID-19 | Yes | - | 422 (27.3%) | - |
No | - | 1033 (72.7%) |
Attitudes and Concerns to Cavvination against COVID-19 | December 2020 | March 2021 | p | |
---|---|---|---|---|
Willingness to vaccinate against COVID-19 * | Yes, as soon as possible | 171 (36.9%) | 507 (44.7%) | 0.001 |
Yes, but only in a few months | 52 (11.2%) | 66 (5.9%) | ||
Yes, but in a year or more | 12 (2.6%) | 22 (1.5%) | ||
No, but I might consider it in the future | 81 (17.5%) | 209 (18.5%) | ||
No, never | 113 (24.4%) | 254 (22.4%) | ||
I cannot make a decision | 34 (7.3%) | 77 (6.8%) | ||
Concerns over vaccination against COVID-19 | Vaccine adverse event | 240 (51.8%) | 741 (47.5%) | 0.265 |
Lack of proper testing of vaccines | 235 (50.8%) | 593 (38.1%) | <0.001 | |
Improper transport/storage | 122 (26.4%) | 209 (13.4%) | <0.001 | |
Lack of effectiveness | 91 (21.2%) | 430 (27.6%) | 0.022 | |
Other | 13 (2.8%) | 98 (6.3%) | 0.015 | |
I have no concerns | 57 (12.5%) | 443 (28.4%) | <0.001 | |
The pandemic is a conspiracy | 66 (14.3%) | 149 (9.6%) | 0.015 | |
Past vaccinations | Yes, only mandatory | 251 (52.2%) | 920 (59%) | 0.744 |
Yes, mandatory and recommended | 188 (40.6%) | 572 (36.7%) | ||
No | 24 (5.2%) | 67 (4.3%) |
Variable | Willingness to Get Vaccinated against COVID-19 * (* n = 1598) n (%) | Mandatory Vaccinations (n = 1559) n (%) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Yes, as Soon as Possible | Yes, but Only in a Few Months | Yes, but in a Year or More | No, but I Might Consider It in the Future | No, Never | I Cannot Make a Decision | p | Yes | No | I Do not Have an Opinion | p | ||
Gender | Female | 554 (43.9) | 94 (7.5) | 28 (2.2) | 226 (17.9) | 262 (20.7) | 98 (7.8) | <0.001 | 529 (40.9) | 518 (40.0) | 247 (19.1) | <0.001 |
Male | 124 (37) | 24 (7.2) | 6 (1.8) | 64 (19.1) | 104 (31) | 13 (3.9) | 93 (35.2) | 140 (53.0) | 31 (11.7) | |||
Age | 18–29 | 299 (37) | 57 (7.05) | 20 (2.5) | 181 (22.4) | 189 (23.4) | 63 (7.8) | <0.001 | 275 (35.5) | 364 (37.0) | 135 (17.5) | 0.004 |
30–39 | 207 (46.6) | 35 (7.9) | 10 (2.3) | 61 (13.8) | 104 (23.4) | 27 (6.0) | 193 (42.3) | 175 (38.4) | 88 (19.3) | |||
40–59 | 131 (47.0) | 24 (8.6) | 4 (1.4) | 43 (15.4) | 61 (21.9) | 16 (5.8) | 132 (47.7) | 97 (35.0) | 48 (17.3) | |||
≥60 | 41 (63.1) | 2 (3.1) | 0 (0.0) | 5 (7.7) | 12 (18.4) | 5 (7.7) | 22 (43.1) | 22 (43.1) | 7 (13.8) | |||
Place of residence | Rural area | 124 (33.9) | 24 (6.6) | 7 (2) | 69 (18.9) | 110 (30.0) | 32 (8.7) | <0.001 | 114 (33.5) | 165 (48.6) | 61 (17.9) | 0.004 |
City <50,000 residents | 100 (37.2) | 23 (8.6) | 4 (1.5) | 54 (20.1) | 63 (23.4) | 25 (9.3) | 104 (39.4) | 106 (40.1) | 54 (20.5) | |||
City of 50,000–250,000 residents | 121 (38.2) | 24 (7.6) | 8 (2.5) | 59 (18.6) | 85 (26.8) | 20 (6.3) | 104 (35.7) | 136 (46.7) | 51 (17.5) | |||
City > 250,000 residents | 333 (51.6) | 47 (7.3) | 15 (2.3) | 108 (16.7) | 108 (16.7) | 34 (5.3) | 300 (45.2) | 251 (37.9) | 112 (16.9) | |||
Education | Primary | 4 (36.4) | 3 (27.3) | 0 (0.0) | 1 (9.1) | 2 (18.2) | 1 (9.1) | <0.001 | 3 (30) | 6 (60) | 1 (10) | 0.029 |
Lower secondary | 6 (46.2) | 1 (7.7) | 0 (0.0) | 0 (0.0) | 6 (46.2) | 0 (0.0) | 4 (50) | 3 (37.5) | 1 (12.5) | |||
Vocational | 13 (24.5) | 1 (1.9) | 1 (1.9) | 6 (11.3) | 28 (52.8) | 4 (7.6) | 9 (22.5) | 21 (52.5) | 10 (25) | |||
Secondary education | 201 (37.8) | 31 (5.8) | 10 (1.9) | 101 (19.0) | 147 (27.6) | 42 (7.9) | 167 (36.2) | 221 (48) | 73 (15.8) | |||
University degree | 454 (46.0) | 82 (8.3) | 23 (2.3) | 182 (18.4) | 183 (18.5) | 64 (6.5) | 439 (42.6) | 407 (39.2) | 193 (18.6) | |||
Relationship status | Married | 325 (48.5) | 51 (7.6) | 13 (1.9) | 105 (15.7) | 139 (20.8) | 37 (5.5) | 0.003 | 307 (44.7) | 255 (37.1) | 125 (18.2) | 0.005 |
Civil partnership/Informal relationship | 190 (35.5) | 36 (6.7) | 14 (2.6) | 114 (21.3) | 140 (26.2) | 41 (7.7) | 180 (35.7) | 234 (46.4) | 90 (17.9) | |||
I am not in a relationship | 163 (41.6) | 31 (7.9) | 7 (1.8) | 71 (18.1) | 87 (22.2) | 33 (8.4) | 135 (36.8) | 169 (46.1) | 63 (17.1) | |||
Healthcare professional | Yes | 90 (47.4) | 18 (9.5) | 4 (2.1) | 38 (20.0) | 25 (13.2) | 15 (7.9) | 0.031 | 162 (51.8) | 94 (30.0) | 57 (18.2) | <0.001 |
No | 588 (41.8) | 100 (7.1) | 30 (2.1) | 252 (17.9) | 341 (24.2) | 96 (6.8) | 460 (37.0) | 564 (45.3) | 221 (17.8) | |||
COVID-19 | In the course of the illness | 15 (60.0) | 2 (8.00) | 0 (0.0) | 2 (8.0) | 5 (20.0) | 1 (4.0) | 0.056 | 10 (45.5) | 8 (36.4) | 4 (18.2) | 0.517 |
Convalescent | 94 (38.2) | 22 (8.9) | 3 (1.2) | 63 (25.6) | 47 (19.1) | 17 (6.9) | 95 (35.9) | 115 (43.4) | 55 (20.8) | |||
Has not been ill | 569 (42.9) | 94 (7.1) | 31 (2.3) | 225 (17.0) | 314 (23.7) | 93 (7.0) | 517 (40.7) | 535 (42.1) | 219 (17.2) | |||
Past vaccinations (n = 1133) | Yes, only mandatory | 308 (32.4) | 59 (6.2) | 18 (1.9) | 214 (22.5) | 275 (29.0) | 76 (8.0) | <0.001 | 172 (24.6) | 402 (57.6) | 124 (17.8) | <0.001 |
Yes, mandatory and recommended | 357 (62.9) | 54 (9.5) | 16 (2.8) | 67 (11.8) | 42 (7.4) | 32 (5.6) | 185 (48.7) | 56 (14.6) | 139 (36.7) | |||
No | 13 (16.5) | 5 (6.3) | 0 (0.0) | 9 (11.4) | 49 (62.0) | 3 (3.8) | 13 (23.6) | 38 (69.1) | 4 (7.3) | |||
Chronic conditions (n = 1133) | Yes | 191 (50.3) | 19 (5.0) | 8 (2.11) | 60 (15.8) | 77 (20.3) | 25 (6.7) | 0.155 | 239 (45.2) | 197 (37.2) | 93 (17.6) | |
No | 315 (41.8) | 47 (6.2) | 14 (1.9) | 149 (19.9) | 176 (23.4) | 52 (6.9) | 383 (37.2) | 461 (44.9) | 185 (18.0) |
Type of Concern | Stage I (n = 194) n (%) | Stage II (n = 463) n (%) |
---|---|---|
Vaccine adverse event | 122 (62.9) | 301 (65.1) |
Lack of proper testing of vaccines | 137 (70.6) | 343 (74.1) |
Improper transport/storage | 42 (21.6) | 65 (14.0) |
Lack of effectiveness | 59 (30.4) | 208 (44.9) |
Other | 5 (2.3) | 59 (12.7) |
I have no concerns | 2 (1) | 25 (5.4) |
The pandemic is a conspiracy | 65 (33.5) | 137 (29.6) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Babicki, M.; Mastalerz-Migas, A. Attitudes toward Vaccination against COVID-19 in Poland. A Longitudinal Study Performed before and Two Months after the Commencement of the Population Vaccination Programme in Poland. Vaccines 2021, 9, 503. https://doi.org/10.3390/vaccines9050503
Babicki M, Mastalerz-Migas A. Attitudes toward Vaccination against COVID-19 in Poland. A Longitudinal Study Performed before and Two Months after the Commencement of the Population Vaccination Programme in Poland. Vaccines. 2021; 9(5):503. https://doi.org/10.3390/vaccines9050503
Chicago/Turabian StyleBabicki, Mateusz, and Agnieszka Mastalerz-Migas. 2021. "Attitudes toward Vaccination against COVID-19 in Poland. A Longitudinal Study Performed before and Two Months after the Commencement of the Population Vaccination Programme in Poland" Vaccines 9, no. 5: 503. https://doi.org/10.3390/vaccines9050503
APA StyleBabicki, M., & Mastalerz-Migas, A. (2021). Attitudes toward Vaccination against COVID-19 in Poland. A Longitudinal Study Performed before and Two Months after the Commencement of the Population Vaccination Programme in Poland. Vaccines, 9(5), 503. https://doi.org/10.3390/vaccines9050503